Skip to main content
Tuesday, July 28, 2026
BTC $63,163 ▼ 0.84%
GOKHSHTEIN.
Live WirePoliticsMarketsDigital AssetsTechnologySports
DeFi & On-ChainU.S. EquitiesMacro & RatesResearch
SubscribeGMarkets
Live WirePoliticsMarketsDigital AssetsTechnologySportsDeFi & On-ChainU.S. EquitiesMacro & RatesResearchGMarkets ↗
SubscribeGMarkets →
LIVE
ADA$0.155down−0.59%ETH$1,874down−0.88%LINK$8.31down−0.80%SOL$73.23down−1.23%BTC$63,163down−0.84%XRP$1.06down−0.67%S&P 5007,413up+0.02%Nasdaq24,932down−0.18%Dow52,210up+0.51%RUT2,948up+0.62%TNX4.64%down−0.81%TYX5.13%down−0.72%FVX4.40%down−0.66%IRX3.80%down−0.21%VIX18.67up+0.48%GOLD$4,060.10down−0.41%SILVER$57.89down−1.40%OIL$81.91down−0.85%DXY101.47down−0.06%NVDA$196.51down−4.99%AAPL$336.91up+1.17%TSLA$309.22down−1.22%META$593.87down−0.22%MSFT$389.10up+1.94%AMZN$231.39down−0.31%GOOGL$326.56up+2.13%Fear & Greed29 — FearADA$0.155down−0.59%ETH$1,874down−0.88%LINK$8.31down−0.80%SOL$73.23down−1.23%BTC$63,163down−0.84%XRP$1.06down−0.67%S&P 5007,413up+0.02%Nasdaq24,932down−0.18%Dow52,210up+0.51%RUT2,948up+0.62%TNX4.64%down−0.81%TYX5.13%down−0.72%FVX4.40%down−0.66%IRX3.80%down−0.21%VIX18.67up+0.48%GOLD$4,060.10down−0.41%SILVER$57.89down−1.40%OIL$81.91down−0.85%DXY101.47down−0.06%NVDA$196.51down−4.99%AAPL$336.91up+1.17%TSLA$309.22down−1.22%META$593.87down−0.22%MSFT$389.10up+1.94%AMZN$231.39down−0.31%GOOGL$326.56up+2.13%Fear & Greed29 — Fear
GOKHSHTEIN.
Media · Est. 2019
The front page of everything. Breaking news and sharp analysis across politics, markets, crypto, technology, and sports — with live market data built in.
Markets
Market OverviewDigital AssetsU.S. EquitiesMacro & RatesResearch
Editorial
Politics & PolicyTechnologySports BusinessResearch
Terminal
GMarkets ↗Go PRO
Company
AboutEditorial StandardsAdvertiseSubscribe
Legal
Privacy PolicyTerms of ServiceDisclosures
© 2026 Gokhshtein Media. All rights reserved.
PrivacyTermsDisclosures
Tag

Mobileye

1 article

Regeneron Rises 3.4% on Eye Drug Trial Win; Mobileye Gains on $1.5B Auto Deal
U.S. Equities70d ago
Regeneron Rises 3.4% on Eye Drug Trial Win; Mobileye Gains on $1.5B Auto Deal
Regeneron's geographic atrophy treatment met primary endpoint in Phase 3 trial while Mobileye landed multi-year European automaker contract